2EyesVision, an innovative ophthalmic technology company, has launched a €2 million funding round aimed at accelerating its growth and expansion into international markets. This funding will enable the company to consolidate its new business model based on recurring revenues, reinforce its commercial presence, and prepare for sustained, scalable growth.
To date, the funding round has already secured €950,000 from existing investors Bullnet Capital and Innvierte-CDTI, highlighting the strength of the project and the confidence of institutional investors who have supported the company since its inception. Additionally, 2EyesVision recently obtained a €300,000 ENISA Crecimiento loan, enhancing its financial stability and execution capability.
The funds raised will primarily be used to accelerate the time-to-market of its solutions, boost sales, marketing, and business development, consolidate technological development of its platform, and expand the team to enhance operational capabilities. These actions will enable the company to significantly advance into an accelerated growth phase, supported by key strategic alliances and a robust commercial approach.
With the objective of reaching break-even within three years, 2EyesVision is structuring its expansion phase with a potential medium-term exit strategy in mind, having already identified several segments of strategic buyers in its business plan.
"At 2EyesVision, we strive to position ourselves as a global leader in visual health, supported by a highly specialized team. Our goal is to improve global ophthalmic care through innovative solutions. This funding round will enable us to accelerate our national and international growth plans while providing the necessary financial strength to effectively execute our business strategy," says Carlos Dorronsoro, CEO of 2EyesVision.
About 2EyesVision
2EyesVision develops disruptive ophthalmology solutions aimed at enhancing patient experience and clinical decision-making. Its innovative visual simulator, SimVis Gekko, allows patients to preview their future vision before presbyopia or cataract surgery. The next-generation device, SimVis Gekko2, integrates the Pupil Monitoring System, enabling faster, more accurate, and stable alignment for seamless integration into clinical workflows. The company continues to develop new technologies, reinforcing its position as a leader in visual health. 2EyesVision was initially founded by CSIC scientists in collaboration with leading engineers and ophthalmologists. The company has received support from ERC, CSIC, Comunidad de Madrid, the Ministry of Science and Innovation, EIT Health, Horizon 2020 (European Uckenion), Bullnet Capital, Neotec-CDTI, Innvierte-CDTI, ENISA, and Luminate (an international reference fund in optics and photonics based in New York State).
About Bullnet Capital
Bullnet Capital is an independent Spanish venture capital firm focusing on high-tech companies (software, electronics, semiconductors, photonics). Established in 2002, it manages a total of €140 million across various investment vehicles. To date, Bullnet Capital has invested in thirty early-stage Spanish companies, maintaining its investment philosophy of adding value and actively contributing to portfolio companies.
www.bullnetcapital.com
cloud technology axon
Since Suma Capital’s entry in 2020, Gestcompost has quadrupled its E...
